Skip to content
  • Sunday, 26 July 2026
  • 2:50 am
  • Follow Us
Lab DB
  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ
  • Home
  • Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare
Laboratory Automation & Robotics

Eli Lilly Commits Up to $3.8 Billion to Acquire AtaiBeckley, Betting on the ‘God Molecule’ 5-MeO-DMT for Transformative Mental Healthcare

Lana Keisha Jul 24, 2026 0

Indianapolis, IN – Pharmaceutical giant Eli Lilly has announced a definitive agreement to acquire AtaiBeckley, a clinical-stage biotechnology company focused…

Read More
Pharmaceutical R&D

Samsung Biologics to Acquire PolyPeptide Group for SFr1.46 Billion, Expanding Peptide Therapeutics and CDMO Capabilities

Teuku Ryan Jul 21, 2026 0

Samsung Biologics has announced its intent to acquire PolyPeptide Group, a leading contract development and manufacturing organization (CDMO) specializing in…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.

Dwi Wanna Jul 20, 2026 0

A collaborative study conducted by researchers at the University of Michigan and the University of California San Diego has identified…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

Dwi Wanna Jul 10, 2026 0

The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.

Dwi Wanna Jun 21, 2026 0

This seminal research, conducted by a collaborative team from the University of Michigan and the University of California San Diego,…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.

Dwi Wanna Jun 3, 2026 0

A collaborative research effort between the University of Michigan and the University of California San Diego has identified a critical…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

Dwi Wanna May 12, 2026 0

In a breakthrough study published in the Journal of Clinical Investigation, researchers from the University of Michigan and the University…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

Dwi Wanna May 4, 2026 0

Researchers from the University of Michigan and the University of California San Diego have published a groundbreaking study identifying the…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels.

Dwi Wanna Apr 27, 2026 0

This fundamental discovery, detailed in a collaborative study by researchers from the University of Michigan and the University of California…

Read More
Stem Cell & Regenerative Medicine

Breast cancers that disseminate to bone marrow acquire aggressive phenotypes through CX43-related tumor-stroma tunnels

Dwi Wanna Apr 6, 2026 0

The persistence of estrogen receptor-positive (ER+) breast cancer remains one of the most formidable challenges in modern oncology, as patients…

Read More

Posts pagination

1 2
FDA Reverses Course, Agrees to Review Moderna’s mRNA Flu VaccineRevolutionizing Neuroscience: Andreas Pfenning Unlocks Brain Heterogeneity for Targeted TherapiesLow-frequency vector electrometry with a Rydberg dipolar chainKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
MEDVi Under Scrutiny: AI-Powered Telehealth Startup Faces FDA Warnings, Deceptive Marketing Allegations, and Multiple Lawsuits Despite Meteoric GrowthLLMOps in 2026: The 10 Tools Every Team Must HaveJapan’s FY26 NHI Drug Price Revision: Deeper Dive into Mechanisms and Market ImpactThe Most Favored Nation (MFN) Policy’s Unforeseen Ripple Effect: European Pharmaceutical Launches and Withdrawals Plummet
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’sKing’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid DecompositionSanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
YOU MAY HAVE MISSED
Laboratory Automation & Robotics
Remepy, a startup that pairs drugs with AI-driven apps, clears a Phase IIa test in Parkinson’s
Lana Keisha Jul 25, 2026
Neuroscience & Brain Research
King’s College London Researchers Identify Potential Breakthrough Alzheimer’s Treatment Through Repurposed Spinal Cord Injury Drug KCL-286
Rifan Muazin Jul 25, 2026
Advanced Materials Science
Living Plastics That Self-Destruct: Scientists Engineer Microbe-Embedded Polymers for Complete and Rapid Decomposition
Nila Kartika Wati Jul 25, 2026
Pharmaceutical R&D
Sanofi Discontinues Amlitelimab Development in Atopic Dermatitis, Citing Lack of Meaningful Differentiation
Teuku Ryan Jul 25, 2026

Copyright © 2025 | Powered by WordPress | News Gadgets by ThemeArile

  • Home
  • About Us
    • About Us
    • Affiliate Disclosure
    • Cookie Policy
    • Disclaimer
    • Privacy Policy
    • DMCA
    • Terms of Service
  • Contact Us
  • FAQ